✓ Credit card payment restored — secure checkout via Privacy Shield

Dinex Ec

Dinex EC (Didanosine 250/400 mg) — Cipla older NRTI for HIV. Reserved for salvage therapy. FDA black-box pancreatitis, lactic acidosis, and peripheral neuropathy warnings.

SKU: Dinex Ec Κατηγορία: , , Ετικέτα:

Medically reviewed by Morgan Ellis — Pharmacy Researcher · 8 years experience  · Last reviewed: May 2026

Encrypted checkout
Crypto pays 10% less
Discreet worldwide delivery
1,400+ customers · 50+ countries

Αυτό το προϊόν είναι προσωρινά εξαντλημένο και μη διαθέσιμο.

Quick Answer

Dinex EC — didanosine 250/400 mg enteric-coated capsule (Cipla). NRTI for HIV — older agent, now reserved for salvage therapy or settings where modern NRTIs are unavailable. Mitochondrial toxicity (peripheral neuropathy, pancreatitis, lactic acidosis) limits use.

What you get with MedsBase:

  • WHO-GMP certified manufacturer
  • Discreet plain-envelope packaging
  • Worldwide shipping
  • Rated by 1,400+ customers (read reviews)

📦 Reshipment Assurance: if your order has not arrived 20 business days after dispatch, we reship it at no extra cost. Read the policy.

Why order from MedsBase

Dinex EC ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor — never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.

FDA black-box: pancreatitis + lactic acidosis
Didanosine carries multiple black-box warnings: fatal lactic acidosis with hepatic steatosis (especially with stavudine or in pregnancy), severe pancreatitis (5-7% incidence — fatal cases reported), peripheral neuropathy (12-34%), retinal changes/optic neuritis. Modern HIV care has largely retired didanosine.

Frequently Asked Questions

Why is didanosine still used?

Resource-limited settings, salvage regimens after multiple-drug-resistant HIV, or specific historical situations. Modern guidelines use TDF or TAF (or abacavir) + lamivudine/emtricitabine instead — much better safety profile.

Pancreatitis warning?

5-7% develop pancreatitis. Stop immediately if abdominal pain + raised amylase/lipase. Avoid combining with other pancreatitis-risk drugs (alcohol, valproate, hypertriglyceridaemia).

Peripheral neuropathy?

Common (12-34%) and dose-related. Usually reversible if drug stopped early. Stavudine combination compounds risk — never combine d4T + ddI.

Lactic acidosis?

Mitochondrial toxicity feature. More common with d4T+ddI combination, in women, in pregnancy, in obesity. Symptoms: malaise, fatigue, abdominal pain, breathlessness, nausea. Stop drug immediately.

Drug interactions?

Tenofovir + didanosine raises ddI levels — avoid combination or reduce ddI dose. Allopurinol raises ddI levels (avoid). Methadone reduces ddI levels (clinically minor).

Pregnancy?

Avoid in pregnancy due to lactic acidosis risk (especially with d4T).

What if I miss a dose?

Take when you remember if same day; otherwise skip. Do not double up. Adherence is critical — and this drug is hard to take consistently due to food restrictions and side effects.

Empty stomach?

Older formulations needed empty stomach; the EC formulation is taken on an empty stomach (1 hour before or 2 hours after a meal) — food reduces absorption ~50%.

When should it be stopped?

Severe pancreatitis (any), peripheral neuropathy progression, lactic acidosis, retinal changes, or virological failure all mandate stopping or substituting. Most patients on ddI in modern care should be discussed with HIV specialist for switch to safer alternatives.

Long-term outlook?

Almost all HIV patients in modern care should be on a TDF or TAF or abacavir-based regimen with INSTI third agent. Continued ddI use should be reviewed at every clinic visit with a clear plan to switch when safer alternatives become available.

Other HIV & Antiviral Medications

  • Trioday — TDF + 3TC + EFV — single-tablet regimen by Cipla
  • Triomune — d4T + 3TC + NVP — older 3-in-1 (stavudine-based)
  • Zepdon — raltegravir 400 mg — integrase inhibitor
  • Abamune L — abacavir + lamivudine — alternative NRTI backbone
  • Tenvir L — tenofovir + lamivudine — alternative NRTI backbone
Medical Disclaimer: HIV treatment is a complex, lifelong therapy. Drug choice depends on genotype, resistance testing, comorbidities, and prior treatment history. Discuss any regimen change with an HIV specialist. Adherence >95% is required to prevent resistance. Test for HBV before starting any tenofovir-, lamivudine-, or emtricitabine-containing regimen — withdrawal can cause severe HBV flare in co-infected patients.

More options in HIV Medication

Ranked by recent MedsBase order volume — what other customers in this category are picking.

Strength

250 mg, 400 mg

Quantity

30 Tablet/s, 60 Tablet/s, 90 Tablet/s

Pharma Form

Tablet/s

Manufacturer

Cipla Inc

Treatment

HIV Infection

Generic Brand

Didanosine

Κριτικές

Δεν υπάρχουν ακόμη κριτικές

Προσθήκη κριτικής
Dinex Ec Dinex Ec
Αξιολόγηση*
0/5
* Η αξιολόγηση είναι υποχρεωτική
* Η απάντηση είναι υποχρεωτική
Η κριτική σας
* Η κριτική είναι υποχρεωτική
Όνομα
* Απαιτείται όνομα
Προσθέστε φωτογραφίες ή βίντεο στην κριτική σας

Ερωτήσεις & Απαντήσεις

Κάντε μια ερώτηση
Dinex Ec Dinex Ec
Η ερώτησή σας
* Απαιτείται ερώτηση
Όνομα
* Απαιτείται όνομα
Δεν υπάρχουν ακόμα ερωτήσεις